Indegene IPO 5 Best insights to invest
Share With Friends
IPO investing is always fascinating for retail investors towards the secondary market. While it is good to invest in the primary market (IPO investing), it is also important to understand the details about the company before investing in the IPO.
Most of the time I feel, retail investors invest in any IPO during the bull market without understanding the company management or products. I can say this is not a good process in the long run. You might gain in some companies but during the bear market, the retail investors may lose money if the company is not worthy.
Table of Contents
Let us discuss what are the best points about Indegene IPO and why I considered investing in the company IPO.
Indegene IPO 5 Best insights before investing
#1 – Indegene IPO Unique Business Model
Indegene is a commercialization company focused mainly on the global life sciences industry. In other words, Indegene is a service provider that offers research and development and management services to healthcare and pharmaceutical enterprises focusing on the life science segment.
The company helps healthcare organizations such as biopharmaceutical, emerging biotech, and medical devices companies in patient management, drug discovery, etc. using technology, and integrating analytics.
Indegene is a ‘digital-first’ commercialization firm and has set its sights exclusively on the global life sciences sector, empowering biopharmaceutical, emerging biotech, and medical devices companies to develop and launch products with unparalleled efficiency and efficacy.
#2 – Indegene Unique Services
Indegene engaged in Strategy and consulting, creative and content services, marketing operations, data and analytics, patient services, and technology transformation.
Broadly the services can be categorised as Enterprise commercial solutions, Enterprise medical solutions, Enterprise clinical solutions, omni-channel activation solutions, and next-technology platform solutions.
#3 – Strong Financial performance
Over the last three years, Indegene’s total revenues grew significantly, from Rs 642.9 crore in FY20 to Rs 1,664.6 crore in FY22. In FY23, also, Indegene is growing at a rapid pace having seen its revenues cross Rs 520.9 crore in the three months ending June 2022.
#4 – Total Addressable Market and Product Positioning
The combined sales of the biopharmaceutical and medical devices segments are expected to reach US$2.1 trillion with biopharmaceuticals constituting 69% to reach US$1.5 trillion. Biopharmaceutical comprises companies that discover, develop, manufacture, and sell drugs (chemical and biological-based) to cure, vaccinate, or alleviate symptoms of medical conditions or diseases.
The total expenditure in life sciences operations is expected to reach US$187 billion by 2025, driven by the rise in the aging population, increasing prevalence of chronic diseases and discovery of new diseases, etc.
Positioned at the intersection of healthcare and technology, Indegene solutions span across different stages of the commercialization lifecycle of drugs and medical devices. The Enterprise Commercial Solutions and the Omnichannel Activation solutions cater to the commercial functions of life sciences companies. Enterprise Medical Solutions and Enterprise Clinical Solutions cater to their medical and R&D functions.
Also Read
#5 – Strong expertise and competitors
The life sciences enterprises have to face stringent regulatory complexities. This industry requires a talent pool with in-depth domain expertise on the journey of a drug or medical device from the research lab to the market to organize and analyze scientific and clinical data, navigate the regulatory landscape and the ethical guidelines within which the industry operates, and to develop the requisite medical content for healthcare professionals, patients, and payers. The scarcity of such talent is a major hindrance in operations.
Indegene has over two decades of experience in this industry. The Indegene company was incorporated on October 16, 1998, under the leadership of founding members and CEO Manish Gupta.
Over the years the company has acquired a few established clients. The company has strong client relationships with 19 of the 20 largest biopharmaceutical companies in the world. As of June 30, 2022, the company had a total of 52 active clients globally.
However, the life science services industry consists of a few well-established players with whom Indegene has to compete to get the client. A few of them are Accenture, Capgemini, and Cognizant. A list of life science providers is given below.
Indegene IPO 5 Best insights to invest
With above analysis, I can conclude that if you are interested to gain from the Indegene IPO, invest for long term. The growth potential for the industry is good and Indegene has well positioned its services. You can share your thoughts on this analysis.
Thank you for reading and sharing this with your friends. Your advice and suggestions are welcome. Happy investing.
What Indegene Company Does
Indegene company offers management and consulting services to the biopharmaceutical, emerging biotech and medical device companies develop products, get them to the market, and grow their impact through the life cycle in a more efficient way.
Should I invest in Indegene IPO?
Indegene IPO seems good for investment for long term. You can learn the details in the article “Indegene IPO 5 Best insights to invest”.
More From Across our Website
We endeavor to help you to understand different aspects of a company before you invest in the company’s IPO. Learn all company insights for investment in new companies in the Indian share market in 2023. To know more information about company insights for investment, and business overview of companies to invest, here are some suggested readings on company insights for investment – Green Hydrogen Companies in India, Green Hydrogen Stocks in India, 10 Best IPOs in 2022, Tata Motors Stock Price, Tata Play IPO, Upcoming IPOs, Upcoming SME IPOs, Tesla Stock Price, Tata Technologies IPO.